CHICAGO (Reuters)—Three U.S. children infected with the coronavirus are being treated for a rare inflammatory syndrome that appears similar to one that has raised concerns by doctors in Britain, Italy and Spain, a specialist treating the patients told Reuters. All three—who range in age from 6 months to 8 years—have undergone treatment at Columbia University…
Diagnosing Anti-MOG Autoimmune Encephalomyelitis
A case study of a 7-year-old girl who is eventually diagnosed with anti-MOG autoimmune encephalomyelitis highlights the necessity of a multi-disciplinary approach to inflammatory brain disease…
No Evidence to Support Biologic Switching Guidelines for JIA
NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say. The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second…
Pediatric Rheumatology on Point: Explore Breakthroughs & Networking Opportunities at the 2019 ACR/ARP Annual Meeting
New in 2019, pediatric rheumatologists will be able to network in a community lounge, as well as attend the cutting-edge educational sessions specific to the field. Here’s a sneak peek…
Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
Health Canada has approved adalimumab for treating chronic non-infectious anterior uveitis in patients 2 years and older…
Arthralgias in Children: What to Do When Kids Present with Joint Pain
The evaluation of a child with arthralgia who has a normal physical examination provides a challenge to rheumatologists. Here are some insights into assessing and treating children with musculoskeletal pain syndromes…
Long-Term Canakinumab Treatment Has Favorable Effect on Systemic Features & Joint Health for sJIA
During a five-year trial of canakinumab, patients with systemic juvenile idiopathic arthritis taking canakinumab showed progress toward clinical remission and glucocorticoid tapering…
FDA Approves Subcutaneous Tocilizumab for Ages 2–17
The FDA has approved subcutaneous tocilizumab for treating active systemic juvenile idiopathic arthritis in pediatric patients as young as 2 years old…
Gene Expression Signature Useful for Diagnosing Kawasaki Disease
NEW YORK (Reuters Health)—A 13-transcript whole-blood gene expression signature accurately differentiates Kawasaki disease (KD) from other febrile conditions in children, researchers report. “We believe it is feasible to turn the signature into a diagnostic test,” Dr. Michael Levin from Imperial College London, London, tells Reuters Health by email. “There are a range of methods to…
Rituximab Use Increasing in Treatment of Pediatric Vasculitis
According to a large cohort study of pediatric patients, rituximab use is on the rise in the treatment of children diagnosed with vasculitis. Treatment with cyclophosphamide remains common, but it’s beginning to wane. Dialysis and mechanical ventilation also remain common, the study indicates. The retrospective study of hospitalized children in the U.S. included the largest…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 10
- Next Page »